Healthcare's Biggest Disruption Isn't AI. It's the End of Treatment.

I spent four brilliant days at the World Health Expo in Dubai this week - the world's largest healthcare event. 235,000 visitors, 4,300 exhibitors, 180 countries. And the thing that stopped me in my tracks wasn't a robot or an algorithm.

It was a 15-minute procedure.

Dr Zahid Khan from Danat Al Emarat Hospital for Women & Children in Abu Dhabi described how clinicians are now harvesting ovarian tissue from women in a short laparoscopic procedure, cryopreserving it, and reimplanting it years later near menopause - delaying the onset by 10 to 15 years. A Yale study published last year modelled the outcomes: for a woman in her mid-twenties, the delay could be even longer. Potentially decades. And they're doing this right now!

When a treatment pathway changes, that's a clinical matter. When an entire treatment category disappears, that's a governance matter.

This isn't treatment. It's elimination.

And here's what I noticed in the room: some of the other panellists - whose entire businesses are built around the ongoing management of menopause - looked uncomfortable. Because if you can delay or prevent the condition altogether, what happens to the industry built around treating it?

This wasn't a one-off. Across WHX, the same pattern kept emerging. Innovation isn't just improving patient outcomes… it's threatening to make entire treatment categories redundant. From gene therapies that fix conditions at source to diagnostic tools that catch disease before symptoms even appear. We're not just getting better at treating illness. In certain areas, we're moving beyond it.

And that is where it gets interesting for people like me.

Because the moment healthcare shifts from treatment to cure - or from management to prevention - it doesn't just disrupt clinical practice. It disrupts everything around it. Insurance models built on chronic condition management. Workforce planning designed around long-term patient pathways. Pharmaceutical pipelines predicated on repeat prescription. Regulatory frameworks that assume ongoing treatment as the default. Hospital capacity planning. Procurement cycles. Public health budgets.

I've spent 15 years sitting at exactly this intersection. As the UK's elected Leader of Local and Regional Government, I worked hand in hand with Government on health policy and regulation. In one of my other roles as Leader of a major UK City Region, I chaired health oversight boards for half a million residents and oversaw healthcare commissioning - making decisions about hospital capacity, service provision, and public health strategy while balancing them against education, housing, transport, and regeneration. All competing for the same budget. All politically sensitive. All with real consequences.

When a treatment pathway changes, that's a clinical matter. When an entire treatment category disappears, that's a governance matter. It affects workforce, infrastructure, budgets, and political commitments. The clinical breakthrough is the easy part. The system response is where most governments and health systems get stuck.

And this is precisely where the GCC has an advantage.

The UAE and Saudi are building health systems, cities, and infrastructure simultaneously. They're not retrofitting innovation into legacy systems designed 70 years ago. They can design regulatory frameworks, insurance models, and workforce plans around where healthcare is going - not where it's been. Ashraf Mallak, MD of MSD Pharmaceutical Manufacturing, made this point powerfully on a panel at WHX: the GCC is leading the world in how it structures public-private partnerships in healthcare. The speed and pragmatism here is something I wish I'd seen more of in the UK.

But speed alone isn't enough. The risk is real too. If regulation and policy don't keep pace with the innovation - not just in timescale but in application - they become the bottleneck. Session after session at WHX came back to this tension. Get it right and you accelerate everything. Get it wrong and you hold back an entire industry while the rest of the world moves on.

The governments and health systems that will thrive aren't the ones with the best technology. They're the ones with the governance structures, the regulatory agility, and the board-level experience to translate clinical breakthroughs into system-wide change - fast, and without breaking everything in the process.

That's the conversation that isn't happening enough… and it's the one I'm most interested in!

Healthcare - not just treatment, but increasingly prevention and disease elimination - is moving more rapidly than ever before. And the system has to keep up.